Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: Pilot study

Journal of Anesthesia

Volumn 27, Issue 4, 2013, Pages 618-622

  Toth, Ildiko ^a   Mikor, Andras ^a,b   Leiner, Tamas ^a   Molnar, Zsolt ^a,b   Bogar, Lajos ^a   Szakmany, Tamas ^a,c,d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c Hamad Medical Coorporation Doha Qatar   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

C reactive protein; Immunoglobulin; Mortality; Organ failure; Procalcitonin; Respiratory failure; Septic shock

Indexed keywords

C REACTIVE PROTEIN; HYPERTENSIVE FACTOR; IGM ENRICHED IMMUNOGLOBULIN; IMMUNOGLOBULIN; PLACEBO; PROCALCITONIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE UNIT; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPTIC SHOCK;

AGED; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PILOT PROJECTS; PROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 84882703365     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-012-1553-9     Document Type: Article

References (18)

1. Flaatten H, Gjerde S, Guttormsen AB, Haugen O, Høivik T, Onarheim H, Aardal S. Outcome after acute respiratory failure is more dependent on dysfunction in other vital organs than on the severity of the respiratory failure. Crit Care. 2003;7:R72-7.
2. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010;36:222-31.
3. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-87.
4. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;4:CD001090.
5. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, Tartamella F, Prisco L, Bigotto F, Bigolin T, Ferluga M, Batticci I, Michelone E, Borelli M, Viviani M, Tomasini A. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167-71.
6. Yavuz L, Aynali G, Aynali A, Alaca A, Kutuk S, Ceylan BG. The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients. J Int Med Res. 2012;40:1166-74.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-55.
8. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-52.
9. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686-92.
10. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Müller-Werdan U. Score-based immunoglobulin therapy of sepsis (SBITS) study group. Crit Care Med. 2007;35:2693-701.
11. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677-85.
12. Rodríguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298-304.
13. Pilz G, Kreuzer E, Kääb S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified post-cardiac patients at high risk for sepsis. Chest. 1994;105:76-82.
14. Kress HG, Scheidewig C, Schmitt H, Silber R. Reduced incidence of postoperative infections following intravenous application of an IgA and IgM-enriched immunoglobulin preparation in anergic patients undergoing cardiac surgery. Crit Care Med. 1999;27:1281-7.
15. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med. 2011;32:569-80.
16. Norrby-Teglund A, Haque KN, Hammarström L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260:509-16.
17. Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, Esen F. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care. 2002;6:357-62.
18. Vincent JL, Nelson DR, Williams MD. Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med. 2011;39:1050-5.